NZ594178A - An ex vivo method of predicting toxicity to tyrosine kinase inhibitors - Google Patents
An ex vivo method of predicting toxicity to tyrosine kinase inhibitorsInfo
- Publication number
- NZ594178A NZ594178A NZ594178A NZ59417807A NZ594178A NZ 594178 A NZ594178 A NZ 594178A NZ 594178 A NZ594178 A NZ 594178A NZ 59417807 A NZ59417807 A NZ 59417807A NZ 594178 A NZ594178 A NZ 594178A
- Authority
- NZ
- New Zealand
- Prior art keywords
- drug
- tyrosine kinase
- cell
- vivo method
- kinase inhibitors
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 231100000419 toxicity Toxicity 0.000 title abstract 2
- 230000001988 toxicity Effects 0.000 title abstract 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title abstract 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 abstract 6
- 229940079593 drug Drugs 0.000 abstract 6
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 3
- 229930195729 fatty acid Natural products 0.000 abstract 3
- 239000000194 fatty acid Substances 0.000 abstract 3
- 150000004665 fatty acids Chemical class 0.000 abstract 3
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5061—Muscle cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/22—Tryptophan; Tyrosine; Phenylalanine; 3,4-Dihydroxyphenylalanine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4706—Regulators; Modulating activity stimulating, promoting or activating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77709606P | 2006-02-27 | 2006-02-27 | |
| US82123006P | 2006-08-02 | 2006-08-02 | |
| US82737206P | 2006-09-28 | 2006-09-28 | |
| US82834506P | 2006-10-05 | 2006-10-05 | |
| US86773606P | 2006-11-29 | 2006-11-29 | |
| PCT/US2007/062871 WO2007101191A2 (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ594178A true NZ594178A (en) | 2013-02-22 |
Family
ID=38459790
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ571465A NZ571465A (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
| NZ594178A NZ594178A (en) | 2006-02-27 | 2007-02-27 | An ex vivo method of predicting toxicity to tyrosine kinase inhibitors |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ571465A NZ571465A (en) | 2006-02-27 | 2007-02-27 | Compositions and methods for reducing cellular fat and for predicting cardiac toxicity and upon treatment with tyrosine kinase inhibitors |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US8709738B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1996939B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5539653B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101390625B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN101438155B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007220094B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2643846A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2475162T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL193715A (cg-RX-API-DMAC7.html) |
| NZ (2) | NZ571465A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007101191A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010036910A1 (en) * | 2008-09-26 | 2010-04-01 | Yoshikazu Ohta | Heart protection by administering an amp-activated protein kinase activator |
| WO2015027171A1 (en) * | 2013-08-23 | 2015-02-26 | Quintiles Transnational Corporation | Methods for predicting toxicity in response to treatment with a drug by assessing activation of the sterol regulatory binding protein (srebp) pathway |
| CA2944181C (en) | 2014-03-27 | 2019-09-17 | Salk Institute For Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| EP3262157A4 (en) * | 2015-02-27 | 2018-12-05 | Salk Institute for Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| EP3485001A4 (en) | 2016-05-25 | 2020-08-12 | Salk Institute for Biological Studies | COMPOSITIONS AND PROCESSES FOR THE PRODUCTION OF ORGANOIDS AND THE MODELING OF DISEASES |
| JP7032723B2 (ja) * | 2017-07-21 | 2022-03-09 | 公立大学法人福島県立医科大学 | 薬剤の心毒性評価方法及びそのための試薬又はキット |
| US11369608B2 (en) | 2017-10-27 | 2022-06-28 | University Of Virginia Patent Foundation | Compounds and methods for regulating, limiting, or inhibiting AVIL expression |
| TWI711458B (zh) * | 2019-07-08 | 2020-12-01 | 大江生醫股份有限公司 | 植物發酵物及其製備方法與用於胃臟保健的用途 |
| KR102493664B1 (ko) | 2020-01-29 | 2023-02-01 | 한국화학연구원 | 심장 독성 예측 모델링 시스템 및 모델링 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9618420D0 (en) * | 1996-09-04 | 1996-10-16 | Scotia Holdings Plc | Fatty acid treatment |
| DE19932555A1 (de) * | 1999-07-13 | 2001-01-18 | Solvay Pharm Gmbh | Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen |
| US20020028826A1 (en) * | 2000-06-15 | 2002-03-07 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| DK1438420T3 (da) | 2001-09-24 | 2010-01-18 | Lipomics Technologies Inc | Fremgangsmåder til anvendelse af kvantitative lipid-metablom-data |
| SG152922A1 (en) * | 2002-11-04 | 2009-06-29 | Univ California | Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body |
| PL1668152T3 (pl) * | 2003-08-28 | 2009-06-30 | Ipsogen | Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka |
-
2007
- 2007-02-27 NZ NZ571465A patent/NZ571465A/en not_active IP Right Cessation
- 2007-02-27 WO PCT/US2007/062871 patent/WO2007101191A2/en not_active Ceased
- 2007-02-27 CN CN2007800136974A patent/CN101438155B/zh not_active Expired - Fee Related
- 2007-02-27 JP JP2008556587A patent/JP5539653B2/ja not_active Expired - Fee Related
- 2007-02-27 AU AU2007220094A patent/AU2007220094B2/en not_active Ceased
- 2007-02-27 CN CN2013101368247A patent/CN103217520A/zh active Pending
- 2007-02-27 ES ES07757542.1T patent/ES2475162T3/es active Active
- 2007-02-27 KR KR1020087023650A patent/KR101390625B1/ko not_active Expired - Fee Related
- 2007-02-27 CA CA002643846A patent/CA2643846A1/en not_active Abandoned
- 2007-02-27 NZ NZ594178A patent/NZ594178A/xx not_active IP Right Cessation
- 2007-02-27 EP EP07757542.1A patent/EP1996939B1/en not_active Not-in-force
- 2007-02-27 US US12/280,893 patent/US8709738B2/en not_active Expired - Fee Related
-
2008
- 2008-08-26 IL IL193715A patent/IL193715A/en not_active IP Right Cessation
-
2012
- 2012-12-26 JP JP2012282502A patent/JP2013063090A/ja active Pending
-
2013
- 2013-04-05 US US13/857,591 patent/US20130288285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20090186910A1 (en) | 2009-07-23 |
| CN101438155B (zh) | 2013-04-24 |
| WO2007101191A2 (en) | 2007-09-07 |
| IL193715A0 (en) | 2009-05-04 |
| EP1996939A4 (en) | 2009-07-15 |
| IL193715A (en) | 2014-06-30 |
| JP2013063090A (ja) | 2013-04-11 |
| AU2007220094A1 (en) | 2007-09-07 |
| EP1996939B1 (en) | 2014-03-26 |
| JP5539653B2 (ja) | 2014-07-02 |
| US8709738B2 (en) | 2014-04-29 |
| US20130288285A1 (en) | 2013-10-31 |
| JP2009533017A (ja) | 2009-09-17 |
| AU2007220094B2 (en) | 2013-12-05 |
| EP1996939A2 (en) | 2008-12-03 |
| CA2643846A1 (en) | 2007-09-07 |
| CN101438155A (zh) | 2009-05-20 |
| ES2475162T3 (es) | 2014-07-10 |
| CN103217520A (zh) | 2013-07-24 |
| NZ571465A (en) | 2011-09-30 |
| KR20090008194A (ko) | 2009-01-21 |
| WO2007101191A3 (en) | 2007-12-13 |
| KR101390625B1 (ko) | 2014-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ594178A (en) | An ex vivo method of predicting toxicity to tyrosine kinase inhibitors | |
| MX349787B (es) | Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido. | |
| CL2009000782A1 (es) | Metodo que comprende un compuesto derivado de oximetilen-arilo sustituido, inhibidores de dpp-iv; y su uso en el tratamiento de la diabetes y disminucion de trigliceridos, entre otras enfermedades. | |
| MX2009002496A (es) | Combinaciones que contienen un derivado de 4-acilaminopiridina. | |
| BRPI0413363A (pt) | formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase | |
| PT1876129E (pt) | Processo e dispositivo para a redução do consumo de energia de uma instalação de elevadores | |
| IL206155A (en) | An in vitro or ex vivo method to increase immune response of immune cells by reducing or inhibiting the cbl-b function of cells, and inhibiting cbl-b or antagonist to use the above method | |
| MX2009002936A (es) | Biomarcadores de la modulacion de objetivo, eficacia, diagnostico, y/o pronostico para los inhibidores de raf. | |
| GB2435118C (en) | Multiprocessor system and boot-up method of slave system. | |
| IL192634A0 (en) | Thiazoles as 11 beta-hsd1 inhibitors | |
| ZA200807862B (en) | Azolopyrimidines as inhibitors of cannabinoid 1 activity | |
| WO2007143146A3 (en) | Method of treating inflammatory diseases using tyroskine kinase inhibitors | |
| TW200722421A (en) | Azole derivatives as inhibitors of lipases and phospholipases | |
| EP2266561A3 (en) | IKK Inhibitors for the Treatment of Endometriosis | |
| TWI351035B (en) | Low-power dram and method for driving the same | |
| NZ571858A (en) | Methods of treating, reducing and inhibiting the appearance of ageing in the skin | |
| TW200638950A (en) | Dosage forms of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | |
| EP2090678A4 (en) | Reactor for the electrochemical treatment of biomass | |
| IL198286A0 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
| WO2008051793A3 (en) | Method of preventing or treating metabolic syndrome | |
| MX2009003102A (es) | INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA. | |
| AU318444S (en) | Retainer for rust inhibitor | |
| EP1881756A4 (en) | TREATMENT OF DISEASES OF THE MICROVASCULAR SYSTEM WITH ACETYLCHOLINESTERASE INHIBITORS | |
| WO2008030735A3 (en) | Biomarkers for assessing response to c-met treatment | |
| MY146444A (en) | Benzooxazol-2-one derivatives as inhibitors of lipases and phospholipases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2014 BY CPA GLOBAL Effective date: 20130718 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 27 FEB 2017 BY CPA GLOBAL Effective date: 20140116 |
|
| LAPS | Patent lapsed |